Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis has reported a net income of $1.97 billion for the first quarter of 2009, a decrease of 14%, compared to $2.31 billion for the same period of 2008.
Subscribe to our email newsletter
The company has reported basic earnings per share of $0.87 for the first quarter of 2009, a decrease of 15%, compared to $1.02 for the first quarter of 2008.
Novartis has reported net sales of $9.71 billion for the first quarter of 2009, a decrease of 2%, compared to $9.91 billion for the prior-year period.
Daniel Vasella, chairman and CEO of Novartis, said: “New products fueled ongoing momentum in pharmaceuticals in the first quarter of 2009, and the fundamentals of the business remain positive. R&D projects are progressing well, and I am pleased with the first approvals of Afinitor, offering hope to advanced kidney cancer patients, and the Ixiaro vaccine against Japanese encephalitis.
“The uncertain economy and currency market volatility create an opportunity to continue to enhance productivity and manage costs. Our aim in 2009 remains to again deliver record underlying net sales and earnings excluding currency effects.”